Lyell Immunopharma Stock Number Of Employees
| LYEL Stock | USD 2.77 0.11 4.14% |
Lyell Immunopharma fundamentals help investors to digest information that contributes to Lyell Immunopharma's financial success or failures. It also enables traders to predict the movement of Lyell Stock. The fundamental analysis module provides a way to measure Lyell Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lyell Immunopharma stock.
Lyell | Number Of Employees |
Lyell Immunopharma Company Number Of Employees Analysis
Lyell Immunopharma's Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Current Lyell Immunopharma Number Of Employees | 224 |
Most of Lyell Immunopharma's fundamental indicators, such as Number Of Employees, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lyell Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lyell Number Of Employees Driver Correlations
Understanding the fundamental principles of building solid financial models for Lyell Immunopharma is extremely important. It helps to project a fair market value of Lyell Stock properly, considering its historical fundamentals such as Number Of Employees. Since Lyell Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lyell Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lyell Immunopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Employee typically refers to an individual working under a contract of employment, whether oral or written, express or implied, and has recognized his or her rights and duties. Most officers of corporations are included as employees and contractors are generally excluded.
| Competition |
Based on the recorded statements, Lyell Immunopharma is currently employing 224 people. This is 97.96% lower than that of the Biotechnology sector and 58.16% lower than that of the Health Care industry. The number of employees for all United States stocks is 98.81% higher than that of the company.
Lyell Number Of Employees Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lyell Immunopharma's direct or indirect competition against its Number Of Employees to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lyell Immunopharma could also be used in its relative valuation, which is a method of valuing Lyell Immunopharma by comparing valuation metrics of similar companies.Lyell Immunopharma is currently under evaluation in number of employees category among related companies.
Lyell Immunopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lyell Immunopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lyell Immunopharma's managers, analysts, and investors.Environmental | Governance | Social |
Lyell Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 241.71 M | ||||
| Shares Outstanding | 254.94 M | ||||
| Shares Owned By Insiders | 15.00 % | ||||
| Shares Owned By Institutions | 73.23 % | ||||
| Number Of Shares Shorted | 20.1 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 5,883 X | ||||
| Revenue | 130 K | ||||
| Gross Profit | 84.68 M | ||||
| EBITDA | (213.84 M) | ||||
| Net Income | (234.63 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 63.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 2.37 X | ||||
| Cash Flow From Operations | (163.69 M) | ||||
| Short Ratio | 24.99 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 6.33 | ||||
| Number Of Employees | 224 | ||||
| Beta | -0.55 | ||||
| Market Capitalization | 706.18 M | ||||
| Total Asset | 750.03 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 520.17 M | ||||
| Net Asset | 750.03 M |
About Lyell Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyell Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyell Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyell Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Lyell Immunopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Lyell Immunopharma Piotroski F Score and Lyell Immunopharma Altman Z Score analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.Note that the Lyell Immunopharma information on this page should be used as a complementary analysis to other Lyell Immunopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Lyell Stock analysis
When running Lyell Immunopharma's price analysis, check to measure Lyell Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lyell Immunopharma is operating at the current time. Most of Lyell Immunopharma's value examination focuses on studying past and present price action to predict the probability of Lyell Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lyell Immunopharma's price. Additionally, you may evaluate how the addition of Lyell Immunopharma to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Lyell Immunopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Quarterly Revenue Growth (0.95) | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.